Aligos Therapeutics, Inc. (ALGS) is a clinical-stage biopharmaceutical company based in South San Francisco that develops small molecules and oligonucleotide therapies for liver and viral diseases, including chronic hepatitis B, hepatitis delta, and MASH. The company has no approved products and no product revenue, which makes its balance sheet as important to investors as its science. On Tuesday, the stock traded at $1.44, down $0.22, or 13.25%, from the prior session's close of $1.66. The move was unambiguously negative and marked a new all-time low. No fresh company disclosure accompanied the drop; the selling extends a repricing that began with the third-quarter report released on Nov. 6.
The decisive catalyst was the quarterly update, in which Aligos reported $31.1 million in cash, cash equivalents, and investments at Sept. 30, down from $77.8 million at the end of 2025, and said those resources would fund planned operations only into the first quarter of 2027. The filing also carried an explicit warning of substantial doubt about the company's ability to continue as a going concern absent additional capital.
That disclosure matters because the company's central value driver, the Phase 2 B-SUPREME study of pevifoscorvir sodium in chronic hepatitis B, is not expected to deliver topline data until late in the third quarter of 2027 — roughly two quarters beyond the stated runway. The enrollment milestone itself was clean: 131 patients in the HBeAg-positive cohort and 114 in the HBeAg-negative cohort, with 70 having completed 48 weeks of treatment. But investors are now pricing the cost of bridging that gap rather than the quality of the data set. For a company of this size, the practical read-through is dilution through a future equity raise, or a partner deal struck from a position of weakness.
Third-quarter revenue of $2.83 million, supported by a milestone payment from China partner Amoytop, landed well short of consensus expectations near $4.9 million. The loss per share of $2.09 was narrower than expected and research spending fell year over year, but cost discipline is a secondary comfort when the funding question is unresolved. Consensus twelve-month targets across the sell side have been cut sharply in recent days, even as most covering analysts have retained buy-equivalent ratings — a gap that itself illustrates how disconnected near-term liquidity has become from long-term pipeline valuation.
Recent sessions have traded at roughly two to three times the stock's average daily volume of about 55,000 shares, with turnover spiking above 150,000 shares on the sharpest down days. That pattern is consistent with forced or capitulation selling rather than orderly repricing. Technically, the shares are far below their 50-day and 200-day moving averages, which now sit near $5.19 and $6.10 respectively, and Tuesday's session broke beneath the $1.58 low set on Nov. 16 with no visible support below.
The divergence from the broader tape is notable. Aligos has fallen while risk appetite in large-cap technology and the major indices has been firmer, and the decline has run opposite to the modest bounce the stock posted on Nov. 13. The company's own peer group of small-cap liver and infectious-disease developers has been mixed rather than uniformly weak, which points to company-specific rather than sector-wide causation. The macro layer is a genuine headwind: October inflation came in hotter than expected, lifting expectations for tighter policy into December, a regime that raises the discount rate on cash flows sitting years in the future and makes dilutive financings more painful for pre-revenue issuers.
The scale runs from 0, meaning no meaningful news and a move normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Aligos scores 50 out of 100.
The verified news is substantial relative to the company's size: a going-concern disclosure and a revenue shortfall at a micro-cap with a single near-term value driver that sits beyond its stated cash runway. The price move, while severe in absolute terms, was roughly three times the stock's typical daily swing of about 4.4% over the past 60 sessions. Moves of this magnitude or larger occurred four times in that window, and the shares have a well-established habit of double-digit percentage swings. A materially negative catalyst combined with an outsized but not unprecedented move produces a mid-range score.
The near-term agenda is dominated by financing. Any announcement of an equity raise, royalty monetization, or new partnership would be the first real test of how the market prices the company's pipeline in a capital-constrained setting. Aligos has also guided to initiating a chronic hepatitis B cohort for ALG-170675 in the fourth quarter of 2026, with Phase 1 topline data expected in mid-2027, and those milestones depend on Amoytop's funding in China rather than the parent's cash.
Fourth-quarter and full-year 2026 results, expected early next year, will be scrutinized primarily for burn rate and any change to the runway statement. The B-SUPREME topline readout in late Q3 2027 remains the binary event that determines the long-term thesis, but it is far enough away that financing terms, not data, will set the direction of the shares in the interim. Risks include further dilution, program deferrals, and the possibility that a partner demands concessions on economics in exchange for capital.
Tickeron's Trending AI Robots page is a curated view of the platform's strongest automated strategies under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, and this section narrows that universe to the performers actually working now. Bots differ meaningfully by strategy, timeframe, performance metrics, and the symbols they trade, so the featured list changes as conditions shift. For investors navigating volatile micro-caps, reviewing the current leaders is a practical starting point.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 35 cases where ALGS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGS advanced for three days, in 186 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALGS as a result. In 85 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ALGS turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALGS entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.797) is normal, around the industry mean (3.592). P/E Ratio (-0.528) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.680) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. ALGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology